Zeronda Tyler's most recent trade in VYNE Therapeutics Inc was a trade of 3,420 Common Stock done at an average price of $1.7 . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| VYNE Therapeutics Inc | Tyler Zeronda | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.65 per share. | 30 Jun 2025 | 3,420 | 115,073 (0%) | 0% | 1.7 | 5,643 | Common Stock |
| VYNE Therapeutics Inc | Tyler Zeronda | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.58 per share. | 31 Mar 2025 | 8,399 | 118,493 (0%) | 0% | 1.6 | 13,270 | Common Stock |
| VYNE Therapeutics Inc | Tyler Zeronda | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 230,000 | 230,000 | - | - | Stock Option (right to buy) | |
| VYNE Therapeutics Inc | Zeronda Tyler | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.35 per share. | 31 Dec 2024 | 4,675 | 126,892 (0%) | 0% | 3.3 | 15,661 | Common Stock |
| VYNE Therapeutics Inc | Tyler Zeronda | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.88 per share. | 30 Sep 2024 | 84 | 131,567 (0%) | 0% | 1.9 | 158 | Common Stock |
| VYNE Therapeutics Inc | Tyler Zeronda | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.92 per share. | 01 Jul 2024 | 92 | 131,651 (0%) | 0% | 1.9 | 177 | Common Stock |
| VYNE Therapeutics Inc | Tyler Zeronda | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.09 per share. | 01 Apr 2024 | 94 | 131,743 (0%) | 0% | 3.1 | 290 | Common Stock |
| VYNE Therapeutics Inc | Zeronda Tyler | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | |
| VYNE Therapeutics Inc | Tyler Zeronda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 62,500 | 131,930 (0%) | 0% | 0 | Common Stock | |
| VYNE Therapeutics Inc | Tyler Zeronda | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.28 per share. | 01 Jan 2024 | 93 | 131,837 (0%) | 0% | 2.3 | 212 | Common Stock |
| VYNE Therapeutics Inc | Tyler Zeronda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2023 | 62,500 | 69,430 (0%) | 0% | 0 | Common Stock | |
| VYNE Therapeutics Inc | Zeronda Tyler | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2023 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | |
| VYNE Therapeutics Inc | Tyler Zeronda | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.10 per share. | 30 Jun 2023 | 91 | 8,017 (0%) | 0% | 4.1 | 373 | Common Stock |
| VYNE Therapeutics Inc | Tyler Zeronda | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.08 per share. | 31 Mar 2023 | 384 | 8,108 (0%) | 0% | 3.1 | 1,183 | Common Stock |
| VYNE Therapeutics Inc | Tyler Zeronda | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.15 per share. | 31 Dec 2022 | 354 | 173,005 (0%) | 0% | 0.1 | 53 | Common Stock |
| VYNE Therapeutics Inc | Tyler Zeronda | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.22 per share. | 30 Sep 2022 | 353 | 173,359 (0%) | 0% | 0.2 | 79 | Common Stock |
| VYNE Therapeutics Inc | Tyler Zeronda | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 30 Jun 2022 | 354 | 173,712 (0%) | 0% | 0.4 | 138 | Common Stock |
| VYNE Therapeutics Inc | Tyler Zeronda | CFO | Grant, award, or other acquisition of securities at price $ 0.35 per share. | 31 May 2022 | 12,510 | 174,066 (0%) | 0% | 0.3 | 4,332 | Common Stock |
| VYNE Therapeutics Inc | Tyler Zeronda | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.65 per share. | 31 Mar 2022 | 773 | 161,556 (0%) | 0% | 0.6 | 502 | Common Stock |
| VYNE Therapeutics Inc | Tyler Zeronda | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2022 | 75,000 | 162,329 (0%) | 0% | 0 | Common Stock | |
| VYNE Therapeutics Inc | Tyler Zeronda | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2022 | 75,000 | 75,000 | - | - | Stock Options | |
| VYNE Therapeutics Inc | Tyler Zeronda | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.88 per share. | 30 Nov 2021 | 4,187 | 87,535 (0%) | 0% | 0.9 | 3,666 | Common Stock |
| VYNE Therapeutics Inc | Tyler Zeronda | Interim CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.39 per share. | 30 Sep 2021 | 206 | 83,348 (0%) | 0% | 1.4 | 286 | Common Stock |
| VYNE Therapeutics Inc | Tyler Zeronda | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2021 | 60,860 | 60,860 | - | - | Stock Options | |
| VYNE Therapeutics Inc | Tyler Zeronda | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2021 | 60,859 | 83,554 (0%) | 0% | 0 | Common Stock | |
| VYNE Therapeutics Inc | Tyler Zeronda | Interim CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.51 per share. | 30 Jun 2021 | 700 | 22,695 (0%) | 0% | 3.5 | 2,457 | Common Stock |